A Phase 2 Randomized, Double-Blind, Crossover, Controlled, Multi-Center Subject Preference Study of Tivozanib Hydrochloride Versus Sunitinib in the Treatment of Subjects with Locally Advanced and/or Metastatic Renal Cell Carcinoma
Phase of Trial: Phase II
Latest Information Update: 07 Aug 2017
At a glance
- Drugs Tivozanib (Primary) ; Sunitinib
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms TAURUS
- Sponsors AVEO Oncology
- 04 Aug 2017 This trial has been discontinued in Belgium.
- 23 Jan 2014 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 04 Aug 2013 New source identified and integrated (Oregon Health and Science University Institutional Review Board: IRB00009069).